Browsing by Author "Sarkar, Susobhan"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor‐initiating cells
    (Wiley, 2021-09) Dzikowski, Lauren; Mirzaei, Reza; Sarkar, Susobhan; Kumar, Mehul; Bose, Pinaki; Bellail, Anita; Hao, Chunhai; Yong, V. Wee; Pathology and Laboratory Medicine, School of Medicine
    Glioblastomas (GBMs) are highly aggressive, recurrent, and lethal brain tumors that are maintained via brain tumor-initiating cells (BTICs). The aggressiveness of BTICs may be dependent on the extracellular matrix (ECM) molecules that are highly enriched within the GBM microenvironment. Here, we investigated the expression of ECM molecules in GBM patients by mining the transcriptomic databases and also staining human GBM specimens. RNA levels for fibronectin, brevican, versican, heparan sulfate proteoglycan 2 (HSPG2), and several laminins were high in GBMs compared to normal brain, and this was corroborated by immunohistochemistry. While fibrinogen transcript was at normal level in GBM, its protein immunoreactivity was prominent within GBM tissues. These ECM molecules in tumor specimens were in proximity to, and surrounding BTICs. In culture, fibronectin and pan-laminin induced the adhesion of BTICs onto the plastic substratum. However, fibrinogen increased the size of the BTIC spheres by facilitating the adhesive property, motility, and invasiveness of BTICs. These features of elevated invasiveness were corroborated in resected GBM specimens by the close proximity of fibrinogen with matrix metalloproteinase (MMP)-2 and-9, which are proteases implicated in metastasis. Moreover, the effect of fibrinogen-induced invasiveness was attenuated in BTICs where MMP-2 and -9 have been inhibited with siRNAs or pharmacological inhibitors. Our results implicate fibrinogen in GBM as a mediator of the invasive properties of BTICs, and as a target for therapy to reduce BTIC tumorigenecity.
  • Thumbnail Image
    Item
    PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway
    (American Association for the Advancement of Science, 2021-11-05) Mirzaei, Reza; Gordon, Ashley; Zemp, Franz J.; Kumar, Mehul; Sarkar, Susobhan; Luchman, H. Artee; Bellail, Anita C.; Hao, Chunhai; Mahoney, Douglas J.; Dunn, Jeff F.; Bose, Pinaki; Yong, V. Wee; Pathology and Laboratory Medicine, School of Medicine
    Brain tumor–initiating cells (BTICs) drive glioblastoma growth through not fully understood mechanisms. Here, we found that about 8% of cells within the human glioblastoma microenvironment coexpress programmed cell death 1 (PD-1) and BTIC marker. Gain- or loss-of-function studies revealed that tumor-intrinsic PD-1 promoted proliferation and self-renewal of BTICs. Phosphorylation of tyrosines within the cytoplasmic tail of PD-1 recruited Src homology 2–containing phosphatase 2 and activated the nuclear factor kB in BTICs. Notably, the tumor-intrinsic promoting effects of PD-1 did not require programmed cell death ligand 1(PD-L1) ligation; thus, the therapeutic antibodies inhibiting PD-1/PD-L1 interaction could not overcome the growth advantage of PD-1 in BTICs. Last, BTIC-intrinsic PD-1 accelerated intracranial tumor growth, and this occurred in mice lacking T and B cells. These findings point to a critical role for PD-1 in BTICs and uncover a nonimmune resistance mechanism of patients with glioblastoma to PD-1– or PD-L1–blocking therapies.